Bioperfectus Together with Brunei to Fight and Defeat COVID-19

Company news
2022-03-01
  • As one of the listed Covid-19 antigen rapid test kits that are recommended and authorized for use by the Ministry of Health, Brunei Darussalam, Bioperfectus SARS-CoV-2 Ag Rapid Test Kits were sent to Brunei in 3 batches.
  • Upon the request of the Ministry of Health, Brunei Darussalam, Bioperfectus will supply the SARS-CoV-2 Ag Rapid Test Kits with the customized QR code cassettes, which utilizes the tracing & tracking ability of the COVID-19 cases in Brunei.

 

According to the latest COVID-19 cases report, as of March 1, 2022, there are a total of 59,447 COVID-19 cases outbroke in Brunei, for the last 7 days, there is an obvious surge in the local record.

Since December 1, 2021, The Ministry of Health, Brunei Darussalam has appointed 12 clinics and healthcare businesses to issue certificates as proof of individuals taking COVID antigen rapid tests (ART).

 

Bioperfectus SARS-CoV-2 Ag Rapid Test Kits were sent to Brunei in 3 batches after winning the bidding of the Ministry of Health, Brunei Darussalam. Bioperfectus SARS-CoV-2 Ag Rapid Test Kits are recommended and authorized for use based on the evaluation done by the Ministry of Health, Brunei Darussalam.

Upon the request of the Ministry of Health, Brunei Darussalam, Bioperfectus will supply the SARS-CoV-2 Ag Rapid Test Kits with the customized QR code cassettes, which utilizes the tracing & tracking ability of the COVID-19 cases in Brunei.

Together, we will fight and defeat COVID-19.

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14